Back to Search
Start Over
Combined treatment with the histone deacetylase inhibitor LBH589 and a splice‐switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells
- Source :
- Journal of Neurochemistry. 153:264-275
- Publication Year :
- 2020
- Publisher :
- Wiley, 2020.
-
Abstract
- Spinal muscular atrophy (SMA) is a motor neuron disease caused by loss of function mutations in the Survival Motor Neuron 1 (SMN1) gene and reduced expression of the SMN protein, leading to spinal motor neuron death, muscle weakness and atrophy. Although humans harbour the highly homologous SMN2 gene, its defective splicing regulation yields a truncated and unstable SMN protein. The first therapy for SMA was recently approved by the Food and Drug Administration and consists of an antisense oligonucleotide (Nusinersen) rendering SMN2 functional and thus improving patients' motor activity and quality of life. Nevertheless, not all patients equally respond to this therapy and the long-term tolerability and safety of Nusinersen are still unknown. Herein, in vivo splicing assays indicated that the HDAC inhibitor LBH589 is particularly efficient in rescuing the SMN2 splicing defect in SMA fibroblasts and SMA type-I mice-derived neural stem cells. Western blot analyses showed that LBH589 also causes a significant increase in SMN protein expression in SMA cells. Moreover chromatin immunoprecipitation analyses revealed that LBH589 treatment induces widespread H4 acetylation of the entire SMN2 locus and selectively favors the inclusion of the disease-linked exon 7 in SMN2 mature mRNA. The combined treatment of SMA cells with sub-optimal doses of LBH589 and of an antisense oligonucleotide that mimic Nusinersen (ASO_ISSN1) elicits additive effects on SMN2 splicing and SMN protein expression. These findings suggest that HDAC inhibitors can potentiate the activity of Nusinersen and support the notion that 'SMN-plus' combinatorial therapeutic approaches might represent an enhanced opportunity in the scenario of SMA therapy.
- Subjects :
- 0301 basic medicine
medicine.drug_class
SMN1
Biology
Biochemistry
03 medical and health sciences
Cellular and Molecular Neuroscience
Exon
0302 clinical medicine
medicine
spinal muscular atrophy
Settore BIO/16 - ANATOMIA UMANA
LBH589
Histone deacetylase inhibitor
Spinal muscular atrophy
Motor neuron
SMA
medicine.disease
SMN2 splicing
nervous system diseases
Cell biology
Nusinersen therapy
030104 developmental biology
medicine.anatomical_structure
RNA splicing
Nusinersen
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 14714159 and 00223042
- Volume :
- 153
- Database :
- OpenAIRE
- Journal :
- Journal of Neurochemistry
- Accession number :
- edsair.doi.dedup.....777c091ac315ac01864a6fb0f775ed62